Whitehawk Therapeutics, Inc. (WHWK): Gross Profit
$6.38M
Year ended 2025-12-31
-22.8%
3-year compound annual growth
| Period ended | Gross Profit | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $6.38M | -72.2% | 2026-03-12, From 2025-01-01 |
| 2024-12-31 | $22.96M | +6.6% | 2026-03-12, From 2024-01-01 |
| 2023-12-31 | $21.55M | +55.2% | 2025-03-28, From 2023-01-01 |
| 2022-12-31 | $13.88M | n/a | 2024-03-13, From 2022-01-01 |
Gross Profit at similar companies
| Company | Year ended | Gross Profit | Change YoY |
|---|---|---|---|
| Whitehawk Therapeutics, Inc. (WHWK) | 2025-12-31 | $6.38M | -72.2% |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | $5.74M | -64.0% |
| International Stem Cell Corp (ISCO) | 2025-12-31 | $5.07M | -4.8% |
| Jaguar Health, Inc. (JAGX) | 2025-12-31 | $7.74M | -20.5% |
| ProPhase Labs, Inc. (PRPH) | 2025-12-31 | $1.38M | n/m |
| China Pharma Holdings, Inc. (CPHI) | 2025-12-31 | -$131.9K | n/m |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $11.60M | -25.0% |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $6.47M | +177.7% |
| CV Sciences, Inc. (CVSI) | 2025-12-31 | $6.75M | -5.8% |
Compare WHWK, ACRS, ISCO, JAGX side by side · Screen every company in Pharmaceutical Preparations ↗